{"entity":{"id":"andrew-aguirre","kind":"person","name":"Andrew J. Aguirre","aka":[],"tldr":"Uses organoids and functional genomics to find what pancreatic cancers depend on beyond KRAS.","summary":"Andrew J. Aguirre is an Institute Member at the Broad Institute of MIT and Harvard and a physician at Dana-Farber, working on pancreatic ductal adenocarcinoma and KRAS biology. He is known for leading real-time genomic profiling of advanced pancreatic cancer to enable precision medicine, the subject of his selected paper. His laboratory uses patient-derived organoids and functional genomics to find what pancreatic cancers depend on beyond KRAS. He now studies RAS-pathway dependencies and resistance to KRAS and RAS inhibitors.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aguirre%20AJ%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["organoids","kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Institute Member, Broad; Physician, Dana-Farber","institutionId":"broad-institute","specialisms":["Pancreatic cancer","KRAS biology","Organoids"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aguirre%20AJ%5BAuthor%5D"}],"papers":[{"title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","journal":"Cancer Discovery","year":2018,"url":"https://doi.org/10.1158/2159-8290.CD-18-0275","doi":"10.1158/2159-8290.CD-18-0275"}],"orcid":"0000-0002-0701-6203"},"route":"/people/andrew-aguirre/","neighbours":{"cancer":[{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"institution":[{"id":"broad-institute","kind":"institution","name":"Broad Institute of MIT and Harvard","route":"/institutions/broad-institute/"},{"id":"lustgarten-foundation","kind":"institution","name":"Lustgarten Foundation","route":"/institutions/lustgarten-foundation/"}],"paper":[{"id":"paper-yurgelun-germline-second-hits-resected-pancreatic-genet-med-2019","kind":"paper","name":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","route":"/key-papers/paper-yurgelun-germline-second-hits-resected-pancreatic-genet-med-2019/"},{"id":"paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017","kind":"paper","name":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","route":"/key-papers/paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017/"},{"id":"paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018","kind":"paper","name":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","route":"/key-papers/paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018/"}]}}